Web20 gen 2015 · 183 Background: ETS and DpR have been recognized as favorable prognostic factors of metastatic colorectal cancer. However, the effect of tumor shrinkage on clinical outcomes has not yet been reported for metastatic esophageal cancer (mEC). The purpose of the present study is to determine the associations of ETS and DpR with … WebExposure to chemotherapy. The median number of treatment cycles was five (range, 1–26) among 55 patients. Reasons for discontinuation of treatment included disease …
Phase I/II trial of 2-weekly docetaxel combined with cisplatin
Web16 mag 2024 · Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y ; Japan … Web10 apr 2024 · Background Squamous cell carcinoma antigen (SCC-Ag) is a widely used tumor marker of SCC. However, the clinical significance of serum SCC-Ag levels in recurrent esophageal SCC (ESCC) remains unclear. This study aimed to investigate the clinical relevance of serum SCC-Ag levels in patients with recurrent ESCC after surgery. … jb haze\u0027s
食道癌 JCOG8807 臨床試験サマリ OncoTribune
http://www.jcog.jp/document/0807.pdf Web17 set 2024 · JCOG0807 study revealed 2-weekly DCF regimen was less toxic and effective for unresectable or metastatic ESCC, however its efficacy for resectable ESCC as an induction chemotherapy is unknown. Methods. The aim of this study was to clarify the safety and efficacy of 2-weekly DCF regimen for resectable ESCC. Web食道癌の治療にシスプラチンが導入されてから、いくつかのレジメンが利用可能となった。シスプラチン併用の化学療法では15.0-76.2%の奏効割合が報告されており、導入以前 … kwik trip dunker carbs